Table 2 Treatment outcome: studies conducted in malaria endemic countries with >10 patients and follow up data available

Pryor 1967 [49]

New Guinea

99

CLQ 1500 mg/3 days, then 300 mg/wk

NR

average 4.1 mths in hospital plus 6-23 mths out

No change in spleen size, general benefit

Sagoe 1970 [57]

Nigeria

43

PG 100 mg/day

≥6 mths

6 mths

32 improved 11 worsened

Bagshawe 1970 [13]

Kenya

28

PG 100 mg/day

1 - 26 mths

1 -6 mths

16 improved 11 worsened 8 unchanged

Stuvier et al. 1971 [27]

India

14

PQ 15 days, then CLQ 300 mg/wk

6-14 mths

once/mths for ≥6 mths

11/14 spleen size ↓50%

Stuvier et al. 1974 [71]

Uganda

41

CLQ 300 mg/wk or PG 100 mg/day

NR

4- 20 mths

all improved

Bryceson et al. 1976 [60]

North Nigeria

30

PG 100 mg/day

3 - 12 mths

3 mths

12/13 improved (17 lost)

Fakunle and Greenwood 1980 [64]

Nigeria

69

PG 100 mg/day

3 mths

10 wks

2 /40 died plus 8/29 defaulters

De Cock et al. 1986 [52]

Kenya

38

PG 100 mg/day or CLQ 300 mg/wk

NR

NR

13/18 improved (20 lost)

Crane 1986 [2]

Papua NG

148

CLQ 300 mg/wk

lifelong

12-18 mths

146 improved (2 lost)

Gupta et al. 1987 [31]

India

54

CLQ 300 mg, 1 or 2/wk

2 yrs

2 yrs

54 Improved

Mac Onuigbo and Mbah 1992 [76]

Nigeria

39

PG 100 or 200 mg

2 - 12 mths

2 - 12 mths

All improved (10 cured)

Manenti et al. 1994 [79]

Tanzania

312

PMT 25 mg/wk

1 mths

3 mths

208 improved 104 unchanged

A-Elgayoum et al. 2011 [18]

Sudan

54

Single short term treatment (various regimens)

1 d to 1 wk (often repeated)

15 –24 mths

36 improved 12 worsened 6 unchanged

Alkadarow et al. 2013 [69]

Sudan

33

CLQ 300 mg/wk

3 mths

3 mths

14/21 improved (12 lost)